<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172493</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00018947</org_study_id>
    <secondary_id>NCI-2019-06087</secondary_id>
    <secondary_id>ONC-19132-L</secondary_id>
    <secondary_id>STUDY00018947</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT04172493</nct_id>
  </id_info>
  <brief_title>Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients</brief_title>
  <official_title>Hyperspectral Endoscopy Imaging for Early Detection of Precancerous Lesions in Average Risk Patients: Proof of Principle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies whether hyperspectral endoscopy improves visualization of abnormal tissue
      in average risk patients during standard-of-care colonoscopies. Hyperspectral endoscopy is an
      emerging technique that has the potential to enable the signals from blood to be resolved
      from tissue-specific signals. Image-enhanced endoscopy may improve visualization of abnormal
      colonic tissue when compared to the standard-of-care high-definition white light endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess whether use of hyperspectral endoscopy (HySE) can improve visualization of
      abnormal colonic tissue.

      SECONDARY OBJECTIVES:

      I. To assess whether use of HySE could reduce the rate of missed flat polyps.

      II. To assess whether use of HySE might in the future reduce the incomplete resection rate
      (IRR).

      III. To examine accuracy of practitioners in predicting polyp histology.

      OUTLINE:

      Patients undergo standard of care white light endoscopy and hyperspectral endoscopy during
      routine colonoscopy procedure.

      After completion of study, patients who experience a colonoscopy-related severe adverse event
      are followed up until resolution or stabilization of the event.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spectral profiles corresponding to normal versus abnormal colonic tissue</measure>
    <time_frame>1 year</time_frame>
    <description>Will apply a multivariate statistical analysis such as spectral angle mapper to determine whether the spectra are significantly different as determined by light spectral bandwidth measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Image quality</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed by the endoscopist, based on level of confidence in delineating the area of interest. Will assess and compare the number of polyps found by standard light endoscopy and narrow band imaging with hyperspectral endoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging differences in polyp characteristics documented upon post-procedure video review</measure>
    <time_frame>1 year</time_frame>
    <description>Will be compared with the final read of the pathology of the polyps. A Pearson X2 test or equivalent test will be applied. When applicable, Fisher exact test and Pearson X2 test will be used to test for differences in categorical variables, which include analysis of polyp morphologic structure and location. A student t test or equivalent statistical test will be used to test for differences in continuous variables, including polyp diameter.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Patient</condition>
  <arm_group>
    <arm_group_label>Diagnostic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperspectral Endoscopy (HySE)</intervention_name>
    <description>Undergo hyperspectral endoscopy</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Hyperspectral Endoscopic Imaging (HSI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>White Light Endoscopy (WLE)</intervention_name>
    <description>Undergo white light endoscopy</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>White Light Endoscopic Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients scheduled for a standard of care screening or surveillance colonoscopy

        Exclusion Criteria:

          -  Any condition that, in the opinion of the investigator, precludes the patient from
             completion of the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassiliki L Tsikitis</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Vassiliki Tsikitis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

